These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18330534)

  • 1. [New oral antidiabetic agents--clinical perspectives].
    Fischer S; Bornstein SR
    Internist (Berl); 2008 Apr; 49(4):495-501. PubMed ID: 18330534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs on the horizon for diabesity.
    Bailey CJ
    Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].
    Hayakawa N; Suzuki A
    Clin Calcium; 2012 Sep; 22(9):1383-90. PubMed ID: 22932293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding treatment options for type 2 diabetes: the old and the new.
    Pratley RE
    Diabetes Educ; 2009; 35 Suppl 1():4S-11S. PubMed ID: 19218561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck M; Smith U
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
    Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
    Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
    Valerón PF; de Pablos-Velasco PL
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Gouni-Berthold I; Papanas N; Maltezos E
    Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent findings concerning thiazolidinediones in the treatment of diabetes.
    Boden G; Zhang M
    Expert Opin Investig Drugs; 2006 Mar; 15(3):243-50. PubMed ID: 16503761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic therapy effects on bone metabolism and fracture risk.
    Montagnani A; Gonnelli S
    Diabetes Obes Metab; 2013 Sep; 15(9):784-91. PubMed ID: 23368527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.